The global Oligonucleotide Synthesis Market is forecasted to be worth USD 9.91 Billion by 2027, according to a current analysis by Emergen Research. The rapid growth of the global market for oligonucleotide synthesis can be attributed to the growing demand for advanced therapeutic procedures. Besides, the rising research activities in the pharmaceutical and biotechnology industry is expected to drive the market growth further. Moreover, the increasing applications of synthesized oligonucleotides are also likely to augment the market growth over the forecasted timeline.
The lack of standardized regulations for the safe use of synthesized oligonucleotide is anticipated to hinder the market growth during the forecasted period.
The researcher assessing the Oligonucleotide Synthesis market dive deep to unearth intangible facts related to the key restraints, opportunities, and threats expected to shape the progress of the industry during the forecast period, 2020 – 2027. Significant evaluation of other factors such as demand and supply status, import and export, distribution channel, consumption volume, and production capability play a vital role in offering business owners, stakeholders and field marketing personnel a competitive edge over others operating in the same space. All important data are presented in self-explanatory charts, tables and graphic images that can be incorporated into any business presentation.
Key Highlights From The Report
In May 2020, Integrated DNA Technologies , a leading producer of integrated genomics solutions, has announced the opening of a new production facility located in North Carolina’s Research Triangle Park. The plant extends the production capacity of IDT and will provide the east section of the United States with industry-leading turnaround times for its product range. Integrated DNA Technologies also planned the North Carolina plant for the first development of goods in response to the COVID-19 epidemic to aid its clients’ activities related to COVID-19 analysis and testing.
In the forecast timeframe, the research segment is anticipated to dominate the market with CAGR of 13.0%. The increase in the number of genome research projects undertaken by academic research institutes facilitated the dominant market position in this segment.
The largest market is expected to be held by the hospital segment. The high number of inpatient and outpatient hospitalizations combined with the growing requirement for oligonucleotide drugs drives the market growth in the segment to meet the needs of the vast number of people suffering from chronic diseases.
North America is forecasted to be the largest market over the forecast timeframe, mainly due to the growing research & development activities and the increasing amount of oligos-based diagnoses and treatments being approved by food and drug administration.
Key participants include GeneDesign, Inc., Sarepta Therapeutics, Inc., Thermo Fisher Scientific, Inc., Bio-Synthesis, Inc., Agilent Technologies, Inc., Biogen Idec International GmbH, Nitto Denko Avecia, Inc., ATDBio Ltd, Integrated DNA Technologies, Inc., and GenScript, Inc. among others.
Request For Free Sample@ https://www.emergenresearch.com/request-sample/351
About Emergen Research
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us: Eric Lee